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1970Objective: This study demonstrated left atrial endocardial dysfunction and platelet activation in patients with
atrial fibrillation and mitral stenosis.
Methods: Study included 80 patients with mitral stenosis and atrial fibrillation (40 each with and without
left atrial thrombosis), 15 healthy volunteers, and 10 left atrial appendage (LAA) specimens from donor
hearts. Blood samples were collected through peripheral vein and left atrium, with peripheral blood samples
of volunteers as controls. LAA specimens were collected during operations. LAA expressions of von
Willebrand factor (vWF) and P-selectin were determined immunohistochemically; plasma concentrations
were measured by enzyme-linked immunosorbent assay. LAA expressions of vWF and P-selectin genes
in were quantitated with real-time fluorescent quantitative polymerase chain reaction.
Results: The difference in vWF and P-selectin plasma levels between left atrial and peripheral venous blood
was not significant; however, peripheral plasma levels of vWF and P-selectin were significantly higher in
those with thrombosis than without thrombosis, which in turn were higher than in healthy subjects.
Both vWF and P-selectin proteins were stained in both left atrial endocardium and cardiomyocytes. The
normalized vWF gene expression relative to control was 3.04 in patients with thrombosis and 2.16 in those
without thrombosis (P < .01). The difference in P-selectin gene expressions among the groups was not
significant.
Conclusions: No differences were observed in plasma levels of vWF and P-selectin between left atrial and
peripheral venous blood. Over expression of vWF gene in LAA may contribute to increased plasma
vWF levels. P-selectin and vWF together may play a role in thrombosis. (J Thorac Cardiovasc Surg
2014;148:1970-6)See related commentary on pages 1976-7.Rheumatic mitral stenosis (MS) combined with atrial
fibrillation (AF) is often associated with left atrial
thrombosis (LAT). The incidence of LAT in patients with
MS confirmed by surgical operation ranges from 17.41 to
24.33%.1,2 Early studies have demonstrated that left atrial
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The Journal of Thoracic and Cardiovascular Suractivation are present in patients with LAT3-5; however,
the mechanisms of platelet activation and endocardial
dysfunction and their relationships with LAT are
still unclear. Plasma von Willebrand factor (vWF) and
P-selectin are considered as biomarkers of endothelium
injury and dysfunction and platelet activation.6 They are
involved in platelet adhesion and aggregation and thus start
the hemostatic process. To evaluate the roles of left atrial
endocardial dysfunction and platelet activation in LAT, the
changes of plasma levels of vWF, P-selectin, and their
gene expressions were studied in left atrial appendage
(LAA) samples from patients with MS and AF.MATERIALS AND METHODS
The study was performed with the permission of our institutional review
board. Individual consents for surgery and collection of LAA and blood
samples were obtained before operation.
Patients and Sampling
Eighty patients with MS combined with long-standing, persistent AF
(40 patients with LAT, 40 without) and 15 healthy subjects were studied.
Patients with chronic obstructive pulmonary disease, hematologic diseases,
stroke, or hepatic or renal dysfunction were excluded. LATwas diagnosed
during surgery. Transthoracic echocardiography was performed for all the
patients before surgery. All 80 patients underwent mitral valve replacement
and bipolar radiofrequency ablation modification of the maze III operation,gery c November 2014
Abbreviations and Acronyms
AF ¼ atrial fibrillation
Ct ¼ threshold cycle
LAT ¼ left atrial thrombosis
MS ¼ mitral stenosis
RT-PCR ¼ real-time polymerase chain reaction
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Das described by Doty and colleagues.7 The LAA was excised during the
operation. Blood samples were collected through a peripheral vein and
the left atrium during the operation. In healthy subjects, only peripheral
blood samples were collected as controls. LAA specimens were obtained
during the radiofrequency ablation in the patients with MS and AF. Ten
LAA specimens were obtained from donor hearts for heart transplant as
controls.
Measurements of Plasma Concentrations of vWF and
P-selectin
Plasma concentrations of vWF and P-selectin were measured by
enzyme-linked immunosorbent assay. Blood samples were stored in
EDTA acid anticoagulation tubes. Plasma was extracted by centrifuging
for 15 minutes at 3000 rpm. Samples were stored at 80C for study.
Human vWF ELISA kit (R&D Systems Inc, Minneapolis, Minn) and hu-
man P-selectin ELISA kit (R&D Systems Inc) were used for detection
and measurement of vWF and P-selectin, respectively.
Detection of vWF and P-selectin Proteins in LAA
Tissue
Detection of vWF and P-selectin protein in LAA tissue was performed
immunohistochemically. LAA specimens were immediately fixed in 4%
paraformaldehyde for 24 hours at room temperature. The LAA tissue
was embedded in paraffin. Serial cryostat sections (4 mm in thickness)
were cut from each tissue block and were immunostained with the
avidin-biotin immunoperoxidase method. Briefly, sections were incubated
with the following solutions in the following order: (1) 2% hydrogen
peroxide for 30 minutes to block endogenous peroxidase activity; (2)
0.3% Triton X-100 (The Dow Chemical Company, Midland, Mich) for
15 minutes to permeabilize the membrane; (3) 10% normal goat serum
for 15 minutes at room temperature to reduce nonspecific antiserum
binding; (4) primary antisera for 16 hours at 4C (1:100 for vWF
and 1:500 for P-selectin); (5) biotinylated goat antimouse at 37C for 45
minutes; and (6) avidin-biotinylated horseradish peroxidase complex
(Abcam Inc, Cambridge, Mass) at 37C for 15 minutes. Immunoreactive
sites were visualized by incubation with 0.025% 3,3-diaminobenzidine
and 0.01% hydrogen peroxide for 3 minutes. Phosphate-buffered saline
solution (pH 7.4) was used to dilute each solution and to wash the
sections 3 times between each step. Tissue sections were counterstained
with hematoxylin. All tissue sections were analyzed under an optical
microscope.
Study of vWF and P-selectin Gene Expressions in
LAATissue
Expressions of vWF and P-selectin genes in LAA tissue were studied
with real-time polymerase chain reaction (RT-PCR). Once collected,
LAA specimens were immediately frozen in liquid nitrogen. Total RNA
was extracted from each tissue sample with Trizol reagent (Invitrogen
Inc, Life Technologies Corporation, Grand Island, NY) according to the
manufacturer’s instructions. Aliquots of the total RNA samples were
diluted in TE buffer, and the concentration of each sample was measuredThe Journal of Thoracic and Carat 260 nm (A260) with a spectrophotometer (BioPhotometer, Eppendorf
AG, Hamburg, Germany). Gene expression analysis was performed only
when the A260/A280 ratios ranged between 1.9 and 2.1, and the integrity
of each RNA sample was confirmed by agarose gel electrophoresis.
RNA was transcribed to complementary DNA with oligonucleotide
primers and subsequently amplified with an M-MLV reverse transcription
kit (Takara Bio Inc, Otsu Japan) according to the manufacturer’s
instructions.
First-strand complementary DNA samples were subjected to quanti-
tative PCR amplification to measure the concentrations of RNA tran-
scripts. RT-PCR was performed with the ABI PRISM 7500 Sequence
Detection System (Applied Biosystems, Life Technologies) and
SYBR Green I (Life Technologies) chemistry. Each of the complemen-
tary DNA samples was examined to assess gene expression levels for
the vWF gene, the P-selectin gene, and the glyceraldehyde 3-
phosphate dehydrogenase gene (housekeeping gene). Oligonucleotide
primers for quantification of vWF, P-selectin, and glyceraldehyde 3-
phosphate dehydrogenase gene transcripts were designed with Primer
Express software (version 1.5; PerkinElmer Inc, Waltham, Mass). All
the PCR analyses were performed with the following cycling condi-
tions: 15 minutes at 95C (initial melt), followed by 40 cycles of 15
seconds at 95C, 1 minute at 60C and 15 seconds at 72C. The spec-
ificity of the primers was verified by 2% agarose gel electrophoresis of
the amplicons.
The 2DDCt method was used to investigate the relative changes of vWF
and P-selectin gene expressions in LAA. The quantification of gene
expression was determined by measuring the threshold cycle (Ct) for
each gene and calculated as follows: Target gene expression ¼ 2DDCt,
where DDCt ¼ DCtStudy group  DCtControl group, with DCt derived as
CtTarget gene  CtHousekeeping gene.
Statistical Analysis
Quantitative data are presented as mean  SD. The difference between
groups was determined by t test and 1-way analysis of variance with the
SPSS statistical software package (version 17.0; IBM Corporation,
Armonk, NY).RESULTS
The clinical characteristics are summarized in Table 1.
Relative to healthy subjects, patients with MS had bigger
left atrium. Among patients with MS, those with LAT had
a bigger left atrium, a smaller mitral valve orifice, and a
longer duration of AF than did those without LAT.
Study on the sections under optical microscopy showed
that the LAA endocardium of MS patient with AF was
rough and was clearly thickened by randomly arranged
new cells. Chronic fiber scarring was present in the
endocardium of patients with LAT, accompanied by new
endothelial cell migration and inflammatory cell infiltration
(Figures 1 and 2). Immunostained vWF and P-selectin
proteins were observed in LAA samples from both donor
hearts (Figures 3 and 4) and patients with MS and AF
(Figures 5 and 6) in both the endocardium and the
cardiomyocytes. The vWF protein was present near
the nuclei, whereas the P-selectin protein was found near
the edge of cardiomyocytes. The stainings of vWF and
P-selectin proteins were weak in donor hearts.
The difference in plasma levels of vWF and P-selectin
between left atrium and peripheral venous blood was notdiovascular Surgery c Volume 148, Number 5 1971
TABLE 1. Clinical data
With
LAT
(n ¼ 40)
Without
LAT
(n ¼ 40)
Control
(n ¼ 15)
Age (y) 53.75  8.38 51.95  7.46 50.93  10.9
Male 19 (47.50%) 18 (45.00%) 8 (53.3%)
Body
weight (kg)
60.21  8.52 65.52  10.10 61.95  9.52
Hypertension 7 (17.5%) 6 (15%) 0
Diabetes 4 (10%) 5 (12.5%) 0
Duration of
AF (mo)
69.80  29.54* 54.83  23.30 —
NYHA
classification
2.68  0.38 2.35  0.34 1.00  0.00
Platelets
(109 cells/L)
185.70  51.19 195.10  41.39 180.6  22.36
Transthoracic echocardiography
LVEF (%) 58.30%  7.61% 60.37%  6.54% 61.46%  3.88%
LVEDD (mm) 43.92  4.51 45.02  4.35 45.93  4.04
LAD (mm) 51.05  7.54y 45.45  6.32z 33.62  2.47
MVA (cm2) 0.88  0.22x 1.11  0.22 —
Data are mean  SD or number of patients. LAT, Left atrial thrombosis; AF, atrial
fibrillation; NYHA, New York Heart Association; LVEF, left ventricular ejection
fraction; LVEDD, left ventricular end-diastolic diameter; LAD, left atrial dimension;
MVA, mitral valve orifice area. *P ¼ .008 versus patients without thrombosis.
yP<.001 versus patients without thrombosis and versus control. zP<.001 versus
patients with thrombosis and versus control. xP < .001 versus patients without
thrombosis and versus control.
FIGURE 2. Immunohistochemical staining for P-selectin in an LAA
sample from a patient with MS and AF. The endocardium is rough and
thickened, and immunostained P-selectin protein can be observed (arrows).
Original magnification 3400.
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The peripheral plasma levels of vWF and P-selectin in
patients with MS and LAT were significantly higher than
those in patients with MS without LATand those in healthy
subjects. The plasma levels of vWF and P-selectin
concentration in patients with MS without LAT were also
higher than those in healthy subjects (Table 2).FIGURE 1. Immunohistochemical staining for vWF in an LAA sample
from a patient with MS and AF. The endocardium is rough and thickened,
and immunostained vWF protein can be observed (arrow). Original
magnification 3200.
1972 The Journal of Thoracic and Cardiovascular SurThe normalized amount of vWF gene expression
relative to control was 3.04 in patients with MS with LAT
and 2.16 in those without LAT. The difference between
groups was statistically significant (Table 3). The difference
of P-selectin gene expression in LAA between different
groups was not significant (Table 4).
DISCUSSION
MS combined with AF is often associated with LAT,
which may induce brain and peripheral artery embolism.
Cardiac enlargement, myocardial remodeling, and hemody-
namic changes caused by MS and AF are important
mechanism for LAT.8,9 In most cases, LAT occurs first in
the LAA, where blood flow is likely to form a vortex
because of the LAA’s structure.10,11FIGURE 3. Immunohistochemical staining for vWF in an LAA sample
from a donor heart. Immunostained vWF protein can be observed near
the nuclei (arrow). Original magnification 3400.
gery c November 2014
FIGURE 4. Immunohistochemical staining for P-selectin in an LAA
sample from a donor heart. Immunostained P-selectin protein can be
observed near the edge of cardiomyocytes (arrow). Original magnification
3400.
FIGURE 6. Immunohistochemical staining for P-selectin in an LAA
sample from a patient with and AF. Immunostained P-selectin protein
can be observed near the edge of cardiomyocytes (arrows). Original
magnification 3400.
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tissue, loss of endothelium, and thrombotic changes of the
endothelium in patients with MS and AF.3,4 Abnormal
platelet activation and endocardial dysfunction were
observed.5 Nonetheless, the mechanism of platelet activa-
tion and endocardial dysfunction and their relationship
with LAT was still unclear.
In our study, a longer duration of AF, smaller mitral valve
orifice area, and larger left atrial dimension were observed
in patients with LAT, which indicated the more advanced
disease. As MS worsens, a progressively high left atrial
pressure develops as a result of the diastolic gradient
between the left atrium and ventricle. The high left atrial
pressure gradually leads to left atrial enlargement and AF.FIGURE 5. Immunohistochemical staining for vWF in an LAA sample
from patient with MS and AF. Immunostained vWF protein can be
observed near the nuclei (arrows). Original magnification 3400.
The Journal of Thoracic and CarThe degree of left atrial enlargement correlates with
the duration of stenotic lesion and involvement by the
underlying rheumatic inflammatory process.12 AF leads to
loss of left atrial contraction, thus increasing the blood
stasis in left atrium secondary to MS. Furthermore, AF
leads to atrial remodeling and endocardial damage, which
increases the risk of thrombosis in the LAA.13
The endothelial system is the largest autocrine,
endocrine, and paracrine organ in human body. Endothelial
cells secrete various vasoactive substances, which may
play an important role in the regulation of vascular tone,
inflammation, lipid metabolism, and particularly in throm-
bosis.14,15 Goldsmith and colleagues3 found endocardial
damage and potentially thrombogenic changes in the atrial
appendages of patients with mitral valve disease. They
thought these anatomic appearances could contribute to
the risk of intra-atrial thrombus formation in patients with
mitral valve disease, especially in the presence of AF.3
Similarly, we found that the endocardium of LAA
specimens from patient with MS and AF was not smooth
and was obviously thickened with randomly arranged new
cells. Chronic fiber scarring was present in endocardium
of patients with LAT, accompanying with new endothelial
cell migration and inflammatory cell infiltration. It has
been shown that fibrosis of the atrial endocardium
exists in patients with solitary AF; however, more atrial
endocardial fibrosis is present in patients with AF and
concomitant mitral valve disease.16
Plasma vWF is a biomarker of endothelial injury and
dysfunction, mediating platelet adhesion to subendothelial
collagen fibers when endothelium injury or dysfunction occurs
and thus initiating the hemostasis pathway.17,18 Left atrial
endothelial dysfunction occurs in patients with MS and AF,
so vWF may play an important role in the formation of LAT.diovascular Surgery c Volume 148, Number 5 1973
TABLE 2. Differences between groups in plasma levels of von Willebrand factor and P-selectin
Patients with LAT (n ¼ 40) Patients without LAT (n ¼ 40) Controls (n ¼ 15)
Left atrium Peripheral vein Left atrium Peripheral vein Peripheral vein
vWF (%) 121.02%  16.77%* 124.15%  13.50%y 104.57%  12.14% 105.42%  7.61% 87.25%  11.52%
P-selectin (ng/mL) 140.79  18.20* 137.22  16.07y 115.68  14.56 111.27  16.33 85.67  9.66
Data are mean SD. LAT, Left atrial thrombosis; vWF, vonWillebrand factor. *P<.001 versus patients without thrombosis and versus controls. yP<.001 versus patients without
thrombosis and versus controls.
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Weibel-Palade bodies of endothelial cells and in the
granules of platelets. In response to a variety of inflamma-
tory or thrombogenic agents, the preformed P-selectin is
mobilized to the cell surface within minutes.15 P-selectin
is considered a plasma marker of platelet activation.
Monitoring of plasma and platelet membrane P-selectin
levels can help to elucidate the extent of platelet
activation.19,20 It is involved in the adhesion of myeloid
cells to activated endothelium and in the adhesion of
platelets to monocytes and neutrophils.21
No significant differences in plasma levels of vWF and
P-selectin concentration between the left atrium and
peripheral venous blood were observed in our study. Chen
and associates22,23 presented similar results in their
study on patients with symptomatic MS undergoing
percutaneous transluminal mitral valvuloplasty. This
suggests that measurements of plasma levels of vWF and
P-selectin concentration in peripheral venous blood might
reflect their plasma levels in the left atrium. The extent of
endothelial injury and dysfunction and platelet activation
could be evaluated by examination of blood samples from
a peripheral vein; however, there is no widely accepted
threshold for vWF or P-selectin levels associated with the
formation of LAT.
Our results demonstrate that left atrial endothelial
dysfunction and abnormal platelet activation exist in
patients with MS combined with AF regardless of whether
LAT is present. The increases in plasma vWF and P-selectin
concentrations was more obvious in patients with LAT than
in patients without LAT. It might be related to the larger left
atrial dimension, smaller mitral valve orifice area, and
longer duration of AF in patients with LAT. Other studies
have presented similar results about changes of plasma
vWF and P-selectin concentration in patients with
MS.8,24,25 Reports on expressions of vWF and P-selectinTABLE 3. Normalized von Willebrand factor gene expression in left atria
Cases CtvWF gene CtGAPDH gen
Patients with LAT 40 17.54  1.52 16.92  1.51
Patients without LAT 40 17.51  1.87 16.39  1.95
Control 10 17.67  1.36 15.44  1.25
Difference between groups was statistically significant (P<.001). Values for all but DDC
aldehyde 3-phosphate dehydrogenase;DCt, derived target gene value (CtTarget geneCtHouse
LAT, left atrial thrombosis.
1974 The Journal of Thoracic and Cardiovascular Surin atrial endocardium are few. Kumagai and colleagues24
investigated the expressions of vWF messenger RNA and
protein in the endocardium by means of immunohisto-
chemistry and in situ hybridization. They found vWF to
be overexpressed in the endocardium of the LAA. This
overexpression was associated with enlarged left atrial
dimensions in mitral valvular disease or increased myocyte
diameters in the underlying myocardium. Endocardial
overexpression of vWF may occur during the process of
atrial structural remodeling, contributing to the thrombotic
predilection of AF in association with underlying heart
disease. In our study, both vWF protein and P-selectin
protein were immunohistochemically stained in the
endocardium of the LAA. Furthermore, vWF protein and
P-selectin protein staining were also observed within
cardiomyocytes, which has not been reported previously.
Literature review did not find any quantitative studies on
expressions of vWF gene and P-selectin gene in the LAA.
The staining of vWF and P-selectin proteins in donor hearts
seem thinner than seen in patients with MS and AF.
We therefore carried out RT-PCR to examine the gene
expressions of vWF and P-selectin.
To the best of our knowledge, the quantitation of gene
expressions of vWF and P-selectin in LAA tissue with
RT-PCR has not been previously reported. The expression
of the vWF gene in the LAA was significantly increased
in patients with MS combined with AF, and this was more
obvious in patients who also had LAT. The changes in
vWF gene expression in the LAA samples from different
groups were related to plasma vWF concentrations. The
overexpression of the vWF gene in the LAA could be an
important contributor to the elevation of plasma vWF
concentration.
Literature review did not find any reports on P-selectin
gene expression in LAA tissue. In an immunohistochemical
study, we found P-selectin protein to be immunostainedl appendage specimens
e DCt DDCt
Normalized vWF gene
expression
0.63  0.26 1.60 3.04
1.12  0.46 1.11 2.16
2.23  0.45 0 1.00
t are mean  SD. Ct, Threshold cycle; vWF, von Willebrand factor; GAPDH, glycer-
keeping gene);DDCt, derived group difference value (DCtStudy groupDDCtControl group);
gery c November 2014
TABLE 4. Normalized P-selectin gene expression in left atrial appendage specimens
Cases CtP-selectin gene CtGAPDH gene DCt DDCt
Normalized P-selectin gene
expression
Patients with LAT 40 27.98  1.94 16.92  1.51 11.06  1.33 0.22 1.16
Patients without LAT 40 27.25  2.04 16.39  1.95 10.86  1.42 0.42 1.34
Control 10 26.72  2.06 15.44  1.25 11.28  1.84 0 1.00
Difference between groups was not statistically significant (P¼ .9850).Ct, Threshold cycle;GAPDH, glyceraldehyde 3-phosphate dehydrogenase;DCt, derived target gene value
(CtTarget gene  CtHousekeeping gene); DDCt, derived group difference value (DCtStudy group  DDCtControl group); LAT, left atrial thrombosis.
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myocytes. RT-PCR was therefore carried out to investigate
the expression of P-selectin in LAA tissue. Although
plasma P-selectin concentration was increased in patients
with MS combined with AF, there was no significant
difference in P-selectin expression in LAA between the
groups. The changes of plasma P-selectin levels had no
relation to changes in P-selectin gene expression in the
LAA or blood platelet count. Other pathways involved in
abnormal platelet activation that cause increased plasma
P-selectin concentration should be further investigated.
Previous studies confirmed that the changes in plasma
vWF level are linked with P-selectin levels. They have
been considered as independent predictors of cardiovascu-
lar events and stroke in patients with AF.23,26 Our results
demonstrate a similar trend in the changes of plasma vWF
and P-selectin levels in patients with MS combined with
AF. Plasma levels of vWF and P-selectin in patients with
MS who also had LAT were found to be significantly
higher than in those patients without LAT and in healthy
subjects. Conversely, plasma levels of vWF and P-selectin
in patients with MS without LAT were shown to be higher
than those in healthy subjects. Patients with LAT had a
larger left atrial dimension, smaller mitral valve orifice
area, and longer duration of AF, which means their
disease was more serious than that in patients without
LAT. The increased vWF, in association with the
disruption of the endocardium, would contribute to the
initiation of thrombogenesis by promoting platelet
adhesion and aggregation on the endocardial surface to
form a platelet membrane. The elevated P-selectin would
guide more platelet aggregation, thus causing the
thrombus to grow further into the atrial lumen. When
significant endothelial dysfunction and platelet activation
occur in patients with MS and AF, vWF and P-selectin
may play a collaborative role in promoting thrombosis as
a response to endothelial injury in the LAA. Monitoring
of plasma vWF and P-selectin levels would be helpful in
delineating the extent of endocardial dysfunction and
platelet activation. Perhaps stronger antiplatelet therapy,
such as dual antiplatelet therapy with clopidogrel and
aspirin, would be beneficial for patients with MS and AF.
Further clinical studies are required.
Some limitations exist in this clinical trial. First,
it represents a small research cohort. The definite time ofThe Journal of Thoracic and CarLAT formation is unclear, and the size of LAT is difficult
to measure during surgery because of its fragility. It is
very difficult to subcategorize the LAT group with regard
to degree of clot burden. Second, this is an initial result of
our research. We found that vWF and P-selectin may play
a collaborative role in thrombosis related to endothelial
injury. Any strategy of stronger antiplatelet therapy for
these patients, however, needs to be confirmed with further
clinical studies. Another research study has reported that the
combination of antiplatelet therapy plus moderate intensity
anticoagulation for patients with AF safely and significantly
decreases the vascular events seen with anticoagulation
alone.27CONCLUSIONS
Left atrial endocardial dysfunction and platelet activation
are present in patients with MS combined with AF. No
differences were observed in plasma vWF and P-selectin
concentrations between left atrial and peripheral venous
blood. The overexpression of the vWF gene in the LAA
may contribute to the increase of plasma vWF levels.
Possibly vWF and P-selectin play a collaborative role to
thrombosis in response to endothelial injury in LAA.References
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155-61.MMENTARYAtrial thrombosis in advanced mitral stenosis with atrial fibrillation:
What should we expect?Carlos-A. Mestres, MD, PhD, FETCSIn this issue of the Journal of Thoracic and Cardiovascular
Surgery, Luo and colleagues1 publish their study intended to
evaluate the role of left atrial endocardial dysfunction and
platelet activation in left atrial thrombosis (LAT). Their
study included 80 patients with rheumatic mitral stenosis(MS) and atrial fibrillation (AF) with (40 patients) or
without (40 patients) LAT. They also evaluated the blood
of 15 apparently healthy volunteers and 10 specimens of
left atrial appendages harvested from donor hearts, looking
at the expressions as well as plasma concentrations of von
Willebrand factor (vWF) and P-selectin protein. Patients
with LAT had bigger left atrial dimensions and smaller
valve orifices. Luo and colleagues1 found no differences
in plasma levels of vWF and P-selectin between the left
atrium and peripheral blood. They concluded that the over-
expression of the vWF gene in the left atrial appendage may
contribute to the increase in plasma vWF levels. What is ex-
tracted from this contribution is that vWF and P-selectin are
supposed to play a collaborative role in thrombosis on the
injured endothelium in left atrial appendage.
Rheumatic MS as a sequela of acute rheumatic fever is a
still common disease in various parts of the world,2 and
because it is a chronic inflammatory disease, a number of
complex phenomena are observed. Subclinical chronic car-
ditis has been previously confirmed by Chopra andgery c November 2014
